Cambridge Cognition develops and commercialises computerised neuropsychological tests of outstanding sensitivity. The company's proprietary technology platform, known as CANTAB®, the Cambridge Neuropsychological Test Automated Battery, is founded on exceptional science originating in the University of Cambridge.

Since its inception in 2002, Cambridge Cognition has embedded its battery of 25 computerised neuropsychological tests into two key market segments: pharmaceutical clinical trials and academic research. CANTAB® is now market leader in each. Its competitive edge is rooted in the extensive scientific validation of the test battery - unparalleled by others in the field.

Through the creation, production and distribution of computerised cognitive tests, we are aiding scientists around the world with their active research on cognition. We are also helping pharmaceutical companies who conduct clinical trials in order to understand the cognitive effects of drugs, especially in conditions like Alzheimer’s disease, Parkinson’s disease, schizophrenia, depression and ADHD.

At Cambridge Cognition we care passionately about improving the understanding, diagnosis and treatment of cognitive disorders. We believe that the prosperity and fulfilment of each of us is a function of how well we develop, deploy, maintain and protect our cognitive resources. We aim to promote cognitive health and well-being throughout life.